Adasuve will now be launched in Sweden, Norway, Finland and

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 30, 2014 at 7:00 AM

Adasuve will now be launched in Sweden, Norway, Finland and Denmark

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that Adasuve now will be launched for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disorder. Medivir entered a license and distribution agreement for the commercialization of Adasuve with Ferrer in September 2013. Adasuve is a brand new inhalable treatment of agitation and is approved by EMA (European Medicines Agency) for sale in Europe. “It is gratifying to be able to launch Adasuve in the four main Nordic countries as a complement to our existing product portfolio” comments Henrik Krook EVP Commercial, Medivir. About agitation More than eight million of the European adult population lives with schizophrenia and bipolar disorder. Market research in the European territory indicates that 15-20 percent of those with schizophrenia and bipolar disorder experience an average of two episodes of agitation each year. The goal of treatment of agitation is to help the patient to gain control of their emotions or anxiety, and to avoid enforcement action that might otherwise have to be used to manage the patient's condition. The standard treatment for acute agitation today consists of antipsychotic drugs, sometimes in combination with benzodiazepines. About Adasuve Adasuve is the first inhalable drug in psychiatry. Adasuve is a non-invasive, fast acting alternative to currently used therapies. Because of its non-invasive form of treatment Adasuve can bring benefits to both patients and caregivers. Adasuve combines the proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung resulting in intravenous-like pharmacokinetics and rapid systemic effects. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics. For more information, please visit www.medivir.com. About Ferrer Ferrer is a privately-held European R&D-based pharmaceutical company headquartered in Barcelona. It is active in the pharmaceutical, health, fine chemicals and food sectors in Europe, Latin America, Africa, the Middle East, Asia and the United States. In total, Ferrer's human healthcare products are commercialized in more than 90 countries, through 23 international affiliates (including joint ventures) and 70 partners and distributors. Ferrer carries out activities throughout the full pharmaceutical value chain, from R&D to international marketing, including fine chemical development and the manufacturing of both raw materials and finished pharmaceuticals. Its research centers in Spain and Germany, and manufacturing sites in Europe and Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and feed sectors. Ferrer holds the commercial rights for Adasuve in Europe, Latin America and the Commonwealth of Independent States countries. About Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non -invasive manner. Adasuve is Alexza's first commercial product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Commission in February 2013. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for Adasuve in Europe, Latin America and the Commonwealth of Independent States countries. Adasuve® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stellus Capital Delivers Solid Q3 Amid Turbulent Times

Unpacking Stellus Capital's Latest Quarter Boy, Stellus Capital sure knows how to keep us on our toes. In a landscape where many are still reeling from the latest market tremors, they post some solid Q3 numbers for September 30, 2026. Not without its hiccups, but hey, who isn’t stumbling a bit right now? Financial Snapshot: Stability Amidst Uncertainty Stellus reported...

Safeguard Global Scores with Atlético Partnership

Kicking Off a New Chapter in Workforce Management Well, when a global workforce giant teams up with a football powerhouse like Atlético de Madrid, it sure does mark a significant play on the field of employment strategies. Safeguard Global has just inked a multi-year partnership with Atlético, signing on as their Official Workforce Partner in Spain. It's not every day...

Americans Grapple with Stagnant Personal Finances: Survey

Americans' Financial Struggles Uncovered The economic landscape seems like a grizzled veteran who's seen its fair share of battles, but lately, it's been hitting families square in the wallet. According to Achieve's latest survey, a stark 71% of Americans are staring at finances that are either stuck in neutral or sliding backwards. Less than half say they’re in a good...

Daycare Drama: Lawsuit Over Child in Traffic Incident

When Chaos Meets Daycare Negligence Fort Worth is no stranger to wild stories, but when a daycare loses a child, you've got a whole different beast. Picture this: a 2-year-old girl, barely tall enough to peek over her own shadow, found by herself on a high-traffic road. That's not just someone's bad day—it's a lawsuit waiting to explode. And boy, has it ever. Parents...

Texas Author's Memoir Journeys Through Trauma and Growth

Finding Clarity Amid Chaos When life throws the unexpected, some folks crumble, but others, like Joyce L. Skala, sift through the rubble for clarity. Her debut memoir, "There's No Such Thing as Bad," weaves through personal chaos—embracing trauma and loss like a late-night poker game where the house always wins. Born from the charred memories of her family's home...

Quest Diagnostics at Jefferies Conference: What’s Next?

Quest Diagnostics Set for the Spotlight in London You're sipping your morning coffee when you hear that Quest Diagnostics (NYSE: DGX) is gearing up for a fireside chat in the UK's capital. Now, this isn't a random chit-chat we're talking about. Sam Samad, the man handling the books as their CFO, will be chatting it up at the Jefferies Global Healthcare Conference on...

Marketing Maven Hosts Claude Workshop for Small Biz

Diving into Claude for Business Out in Ventura County, California, there's a buzz about a fresh, no-cost workshop on deck. Marketing Maven's Lindsey Carnett and Design Main Street's Will Hsiao are teaming up to crack open the potential of Claude for small businesses. And let me tell you, this ain't your typical Monday seminar—it's setting up to provide the golden...

Spotlight on Shenzhen: Malcolm Clarke Unveils a New Lens

A Fresh Gaze on Shenzhen's Dynamic Pulse When's the last time a glossy documentary slapped you awake? That's the vibe Oscar-winning filmmaker Malcolm Clarke is gunning for with his latest, Shenzhen: People Who Build the Future. Forget the cookie-cutter skyline shots, this one's peeling back layers and going beyond the surface gloss. From Pioneers to Futurists: Shenzhen's...

Mesh Security Bolsters Team with Five Cybersecurity Experts

New Blood in Cybersecurity: Mesh's Strategic Moves Ever felt like the cybersecurity world is in a constant game of catch-up? You're not wrong. In today's digital battleground, companies don't just need more tools—they need collective wisdom to bind it all together. And it seems like Mesh Security just caught onto that notion, stacking their deck with five new...

FuelCell Energy Class Action Deadline Looms Amid Loss Reports

November Deadline for FCEL Class Action Participation You've probably seen the stars align in all the wrong ways if you've got stakes in FuelCell Energy, Inc. (NASDAQ: FCEL) right now. A class action lawsuit is breathing down everyone's neck, with a cut-off date of November 10, 2026, to hop aboard. If you bought into FuelCell between June 24 and September 1 of this year,...